

01-23-02

)

Express Mail No. EL715381415US

Docket No. 20347US1 (C38435/111656)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continuation-in-Part Application of:

Heinrich BACHMANN et al.						Examiner	: Unassigned			
Serial	erial No.: Unassigned)		Unassigned			
Filed:		Herewi	th			7.11. 01.11.	Chacoighea			
For:		β,β-CAROTENE 15,15'- MONOOXYGENASES, NUCLEIC ACID SEQUENCES CODING THEREFOR AND THEIR USE)						
				•						
)	N	ew York, New York January 15, 2002				
REQUEST FOR FILING A CONTINUATION-IN-PART APPLICATION										
Box Patent Application Commissioner For Patents Washington, D. C. 20231										
Sir:										
Transmitted herewith for filing is a continuation-in-part patent application under 37 CFR § 1.53(b) of prior pending U.S. Application Serial No. 09/504,393, filed February 15, 2000 by Inventors:										
Heinrich BACHMANN, Roland BRUGGER, Arno Martin FRIEDLEIN, Gabriele Margarethe WIRTZ, Wolf-Dietrich WOGGON, Adrian WYSS, and Markus WYSS										
For:		β,β-CAROTENE 15,15'-MONOOXYGENASES, NUCLEIC ACID SEQUENCES CODING THEREFOR AND THEIR USE								
1.	[x]	The application has 32 pages (including specification, claim pages, and abstract).								
2.	[x]	The declaration and power of attorney								
	a.	[]	has been exe	cuted by all the in	entor/	s; or				

has not been executed by all the inventors. A signed

declaration and power of attorney will be submitted in due course.

b.

- 3. [x] 12 sheets of drawings (Figures 1-8) are enclosed.
- 4. [x] A Sequence Listing is part of this application.
 - a. [x] A Sequence Listing in both paper and computer readable form (diskette) as required by 37 CFR 1.821 et seq. is enclosed.
 - b. [x] Upon information and belief, the content of the paper and computer readable Sequence Listing are the same. See, 37 CFR §§1.821(f).
- 5. [] An associate power of attorney is enclosed.
- 6. [] An assignment of the invention from the Inventor(s) to F. Hoffmann-La Roche AG and an assignment from F. Hoffmann-La Roche AG to ROCHE VITAMINS INC. will follow.
 - a. [] Two checks in the amount of \$40 each are enclosed to cover the recording fees. See paragraph 10.c., below.
 - b. [] Please charge the recording fee to our Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
- 7. [x] Priority is hereby claimed under 35 USC §119 based on Application No. 99103382.0, filed February 22, 1999 in Europe.
 - a. [x] Certified copies of the priority document are already of record in copending U.S. Application Serial No. 09/504,393 filed February 15, 2000.
 - b. [] The certified priority document will follow.
- 8. [x] Priority is hereby claimed under 35 USC §120 based on copending U.S. Application Serial No. 09/504,393, filed February 15, 2000.
- 9. [x] The filing fee is calculated below on the basis of the claims existing in the application plus or minus any claims added or canceled by amendment:

Claims as Filed, Plus/Minus Any Claims Added/Canceled By Amendment

	Number	Number	Basic			
For	Filed	Extra	Rate	Fee = \$	740.00	
Total claims	35 - 20 =	15	x \$18 =	\$	270.00	
Independent claims	6 - 3 =	3	x \$84 =	\$	252.00	
Total Filing Fees				\$	1,262.00	

A check in the amount of \$1,262.00 to cover the filing fee is [x] a. enclosed. If our check is missing or otherwise insufficient, or if any additional fees are required, please charge (or credit any overpayment) to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed. b. Please charge Deposit Account No. 02-4467 in the amount of . A duplicate copy of this paper is enclosed. 10. The Commissioner is hereby authorized to charge payment of the [X] following fees, or to credit any overpayment, to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed. Any additional filing fees required under 37 CFR Section 1.16 not [X] a. otherwise paid by check. Any patent application processing fees required under 37 CFR b. [X] Section 1.17 not otherwise paid by check. Any additional Assignment recording fees under 37 CFR Section C. [x] 1.21 (h) not otherwise paid by check. 11. A Petition For Extension of Time is enclosed to maintain the pendency of U.S. Serial No. _____ filed ____ to which the present application claims benefit. 12. An Information Disclosure Statement is enclosed. 13. [x] Address all communications to: Stephen M. Haracz, Esq. Bryan Cave, LLP 245 Park Avenue New York, NY 10167-0034 tel. (212) 692-1800

Respectfully submitted,

Kevin C. Hooper

Registration No. 40,402

BRYAN CAVE LLP

245 Park Avenue

New York, New York 10167-0034

(212) 692-1800

By:

Docket No. 20347US1 (38435/111656)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	AND THEIR GOL			New York, New	
For:	β,β-CAROTENE 15,15'- MONOOXYGENASES, NUCLEIC ACID SEQUENCES CODING THEREFOR AND THEIR USE)			
Filed:	Herewith)			
Serial No.:	Unassigned)		Unassigned	
Heinrich B	ACHMANN et al.)	Examiner: Unassigned		
In re Contii	nuation-in-Part Application of:)			

New York, New York January 15, 2002

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Mailing Label No.: EL715381415US

Date of Deposit: January 15, 2002

I hereby certify that the following:

- [x] Certificate of Express Mailing (1 p)
- [x] Request For Filing A Continuation-In-Part Application (3 pp) in duplicate
- [x] Specification, Claims and Abstract (32 pp)
- [x] Declaration and Power of Attorney (4 pp) (unexecuted)
- [x] Twelve (12) Sheets of Drawings (FIGS. 1-8)
- [x] Sequence Listing (11 pp)
- [x] One (1) Diskette Containing Computer Readable Sequence Listing
- [x] Check for \$1,262.00 (Filing fee)
- [x] Return postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the Date of Deposit indicated above in an envelope addressed to Box Patent Application, Commissioner For Patents, Washington, D.C. 20231.

Eric Morales

Signature of Person Making Deposit

BRYAN CAVE LLP 245 Park Avenue New York, New York 10167-0034 (212) 692-1800